Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4
2006; Lippincott Williams & Wilkins; Volume: 176; Issue: 5 Linguagem: Inglês
10.1016/j.juro.2006.07.002
ISSN1527-3792
AutoresTimothy J. Daskivich, Meredith M. Regan, William Oh,
Tópico(s)Statistical Methods in Clinical Trials
ResumoNo AccessJournal of UrologyReview article1 Nov 2006Prostate Specific Antigen Doubling Time Calculation: Not as Easy as 1, 2, 4 Timothy J. Daskivich, Meredith M. Regan, and William K. Oh Timothy J. DaskivichTimothy J. Daskivich , Meredith M. ReganMeredith M. Regan , and William K. OhWilliam K. Oh View All Author Informationhttps://doi.org/10.1016/j.juro.2006.07.002AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Although prostate specific antigen doubling time is widely used to predict outcomes such as time to progression and prostate cancer specific mortality, clinicians may be unaware of the impact of method on prostate specific antigen doubling time calculation. We present a critical review of the literature to assess the diversity of methods used to calculate prostate specific antigen doubling time. We then describe the need for methodological consistency with the literature by showing examples from our clinical experience at our institution. Materials and Methods: A comprehensive review of articles evaluating prostate specific antigen doubling time as a prognostic and predictive indicator in various prostate cancer disease states was performed using PubMed. Case examples were drawn from the prostate cancer database at our institution. The database is a registry of 4,651 patients with prostate cancer who have been seen at our institution since 1998. Results: The methodology of prostate specific antigen doubling time calculation is inconsistent in the literature. Based on our experience and data presented in the literature the different methods in the literature are not always interchangeable. Small deviations from the methods outlined in a study can sometimes lead to wide variation in calculated prostate specific antigen doubling time. This variation of up to several months or longer is large enough to cause errors in assessment of prognosis and can even lead to incorrect management. The rules for prostate specific antigen doubling time calculation found in the literature can be categorized into 4 parameter groups, including method, calculation interval, data acquisition rules and data analysis rules. Case examples illustrate the importance of adherence to the literature with regard to each parameter. Conclusions: Consistency with the literature in methodological elements of prostate specific antigen doubling time calculation is essential for the accurate calculation of prostate specific antigen doubling time. Clinicians and researchers should understand how methodological differences influence the value of calculated prostate specific antigen doubling time for purposes of patient care and research. References 1 : Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys1996; 34: 549. Google Scholar 2 : Use of pretreatment prostate specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis2000; 3: S11. Google Scholar 3 : Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol1997; 158: 1876. Link, Google Scholar 4 : Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer1993; 72: 2638. Google Scholar 5 : Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys1997; 38: 941. Google Scholar 6 : Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys2000; 48: 629. Google Scholar 7 : Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol2002; 20: 4567. Google Scholar 8 : Surrogate marker for prostate cancer-specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst2003; 95: 1376. Google Scholar 9 : The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol1994; 152: 1821. Link, Google Scholar 10 : Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol1997; 158: 1441. Link, Google Scholar 11 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Crossref, Medline, Google Scholar 12 : PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc2001; 76: 576. Google Scholar 13 : Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005; 294: 433. Google Scholar 14 : Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol2004; 172: 2244. Link, Google Scholar 15 : The natural history of androgen independent prostate cancer. J Urol2004; 172: 141. Link, Google Scholar 16 : Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology2004; 63: 732. Google Scholar 17 : Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology2003; 62: 128. Google Scholar 18 : Prostate-specific antigen: a surrogate endpoint for screening new agents against prostate cancer?. Prostate2000; 42: 107. Google Scholar 19 : Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol2004; 22: 537. Google Scholar 20 : Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004; 351: 125. Google Scholar 21 : Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA2005; 294: 440. Google Scholar 22 : Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int2004; 94: 295. Google Scholar 23 : Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res1992; 52: 3323. Google Scholar 24 : Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res2004; 10: 3927. Google Scholar 25 : Prostate-specific antigen (PSA) best practice policy. Oncol (Williston Park)2000; 14: 267. Google Scholar 26 : Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys1997; 37: 1035. Google Scholar 27 : Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol1999; 17: 3461. Crossref, Medline, Google Scholar 28 : Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2,304 patients undergoing prostate cancer screening. J Urol2004; 171: 2234. Link, Google Scholar 29 : Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol1997; 157: 2179. Link, Google Scholar 30 : Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol1996; 155: 1977. Link, Google Scholar 31 : Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology1996; 47: 343. Google Scholar Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts© 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byBenecchi L, Pieri A, Destro Pastizzaro C and Potenzoni M (2011) Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer DiagnosisJournal of Urology, VOL. 185, NO. 3, (821-827), Online publication date: 1-Mar-2011.Van Patten C, de Boer J and Tomlinson Guns E (2008) Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial EvidenceJournal of Urology, VOL. 180, NO. 6, (2314-2322), Online publication date: 1-Dec-2008. Volume 176Issue 5November 2006Page: 1927-1937 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsdecision support techniquesprostate-specific antigenprostateprostatic neoplasmsAcknowledgmentsDrs. Anthony D'Amico, Phillip Kantoff and Robert Ross provided review and advice.MetricsAuthor Information Timothy J. Daskivich More articles by this author Meredith M. Regan More articles by this author William K. Oh More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)